TY - JOUR
T1 - Insights into natriuretic peptides in heart failure
T2 - An update
AU - Korinek, Josef
AU - Boerrigter, Guido
AU - Mohammed, Selma F.
AU - Burnett, John C.
N1 - Funding Information:
This article was supported by grants from the National Heart, Lung, and Blood Institute (PO1-HL76611, RO1-HL36634, RO1-HL83231, and HL07111), the Mayo Foundation, Scios, and CoGenesys. Dr. Burnett is Chair of the Scientific Advisory Board of Nile Therapeutics. The Mayo Clinic has licensed designer NPs to Nile Therapeutics and Anexon.
PY - 2008
Y1 - 2008
N2 - Natriuretic peptides (NPs) secreted by the heart in response to volume overload are pleiotropic molecules with vasodilating, diuretic, natriuretic, antiproliferative, and antifibrotic actions. Functioning of the NP system is altered in congestive heart failure (CHF), suggesting that support of the NP system might be beneficial in treatment of acute and chronic CHF. Several approaches alone or in combination with other pharmacologic therapies have been shown to enhance function of the NP system: direct administration of native and designer NPs, inhibition of degradation of NPs and their second messenger (cyclic guanosine monophosphate [cGMP]), and stimulation of cGMP generation. Despite increasing numbers of studies using NPs in therapy of acute and chronic CHF, several controversies regarding safety, efficacy, and dosing of NPs need to be addressed. Moreover, further research is warranted to identify the stages and etiologies of CHF that may profit from NP therapy.
AB - Natriuretic peptides (NPs) secreted by the heart in response to volume overload are pleiotropic molecules with vasodilating, diuretic, natriuretic, antiproliferative, and antifibrotic actions. Functioning of the NP system is altered in congestive heart failure (CHF), suggesting that support of the NP system might be beneficial in treatment of acute and chronic CHF. Several approaches alone or in combination with other pharmacologic therapies have been shown to enhance function of the NP system: direct administration of native and designer NPs, inhibition of degradation of NPs and their second messenger (cyclic guanosine monophosphate [cGMP]), and stimulation of cGMP generation. Despite increasing numbers of studies using NPs in therapy of acute and chronic CHF, several controversies regarding safety, efficacy, and dosing of NPs need to be addressed. Moreover, further research is warranted to identify the stages and etiologies of CHF that may profit from NP therapy.
UR - http://www.scopus.com/inward/record.url?scp=53949104793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53949104793&partnerID=8YFLogxK
U2 - 10.1007/s11897-008-0016-y
DO - 10.1007/s11897-008-0016-y
M3 - Review article
C2 - 18765080
AN - SCOPUS:53949104793
SN - 1546-9530
VL - 5
SP - 97
EP - 104
JO - Current heart failure reports
JF - Current heart failure reports
IS - 2
ER -